 Probucol
"Probucol" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A drug used to lower LDL and HDL cholesterol yet has little effect on serum-triglyceride or VLDL cholesterol. (From Martindale, The Extra Pharmacopoeia, 30th ed, p993).
| Descriptor ID |
D011341
|
| MeSH Number(s) |
D02.755.746
|
| Concept/Terms |
Lurselle- Lurselle
- Hoechst Brand of Probucol
- Aventis Brand of Probucol
|
Below are MeSH descriptors whose meaning is more general than "Probucol".
Below are MeSH descriptors whose meaning is more specific than "Probucol".
This graph shows the total number of publications written about "Probucol" by people in Harvard Catalyst Profiles by year, and whether "Probucol" was a major or minor topic of these publication.
Below are the most recent publications written about "Probucol" by people in Profiles.
-
Massberg S, Byrne RA, Kastrati A, Schulz S, Pache J, Hausleiter J, Ibrahim T, Fusaro M, Ott I, Schömig A, Laugwitz KL, Mehilli J. Polymer-free sirolimus- and probucol-eluting versus new generation zotarolimus-eluting stents in coronary artery disease: the Intracoronary Stenting and Angiographic Results: Test Efficacy of Sirolimus- and Probucol-Eluting versus Zotarolimus-eluting Stents (ISAR-TEST 5) trial. Circulation. 2011 Aug 2; 124(5):624-32.
-
Atsumi H, Kitada M, Kanasaki K, Koya D. Reversal of redox-dependent inhibition of diacylglycerol kinase by antioxidants in mesangial cells exposed to high glucose. Mol Med Report. 2011 Sep-Oct; 4(5):923-7.
-
Tardif JC, McMurray JJ, Klug E, Small R, Schumi J, Choi J, Cooper J, Scott R, Lewis EF, L'Allier PL, Pfeffer MA. Effects of succinobucol (AGI-1067) after an acute coronary syndrome: a randomised, double-blind, placebo-controlled trial. Lancet. 2008 May 24; 371(9626):1761-8.
-
Rabkin DG, Curtis LJ, Weinberg AD, Spotnitz HM. Na+/H+ exchange inhibition and antioxidants lack additive protective effects after reperfusion injury in the working heterotopic rat heart isograft. J Heart Lung Transplant. 2005 Apr; 24(4):386-91.
-
Braun A, Zhang S, Miettinen HE, Ebrahim S, Holm TM, Vasile E, Post MJ, Yoerger DM, Picard MH, Krieger JL, Andrews NC, Simons M, Krieger M. Probucol prevents early coronary heart disease and death in the high-density lipoprotein receptor SR-BI/apolipoprotein E double knockout mouse. Proc Natl Acad Sci U S A. 2003 Jun 10; 100(12):7283-8.
-
Schainfeld RM. Potential emerging therapeutic strategies to prevent restenosis in the peripheral vasculature. Catheter Cardiovasc Interv. 2002 Jul; 56(3):421-31.
-
Gorogawa Si, Kajimoto Y, Umayahara Y, Kaneto H, Watada H, Kuroda A, Kawamori D, Yasuda T, Matsuhisa M, Yamasaki Y, Hori M. Probucol preserves pancreatic beta-cell function through reduction of oxidative stress in type 2 diabetes. Diabetes Res Clin Pract. 2002 Jul; 57(1):1-10.
-
Camargo F, Erickson RP, Garver WS, Hossain GS, Carbone PN, Heidenreich RA, Blanchard J. Cyclodextrins in the treatment of a mouse model of Niemann-Pick C disease. Life Sci. 2001 Nov 30; 70(2):131-42.
-
Oh GT, Choi JH, Hong JJ, Kim DY, Lee SB, Kim JR, Lee CH, Hyun BH, Oh SR, Bok SH, Jeong TS. Dietary hematein ameliorates fatty streak lesions in the rabbit by the possible mechanism of reducing VCAM-1 and MCP-1 expression. Atherosclerosis. 2001 Nov; 159(1):17-26.
-
Erickson RP, Garver WS, Camargo F, Hossain GS, Heidenreich RA. Pharmacological and genetic modifications of somatic cholesterol do not substantially alter the course of CNS disease in Niemann-Pick C mice. J Inherit Metab Dis. 2000 Feb; 23(1):54-62.
|
People  People who have written about this concept. _
Similar Concepts
People who have written about this concept.
_
Top Journals
Top journals in which articles about this concept have been published.
|